Oncolytics Biotech (ONCY) Operating Leases (2018 - 2025)

Oncolytics Biotech (ONCY) has 8 years of Operating Leases data on file, last reported at $563000.0 in Q4 2025.

• On a quarterly basis, Operating Leases changed 0.07% year-over-year to $563000.0 in Q4 2025; TTM through Dec 2025 was $563000.0, a 0.07% change from a year earlier, with the FY2025 full-year figure at $563000.0, changed 0.36% from the prior year.
• Operating Leases for Q4 2025 stood at $563000.0, up from $404735.7 in the prior quarter.
• Over the last five years, Operating Leases for ONCY reached as high as $703523.3 in Q1 2024 and fell as low as $213015.3 in Q4 2023.
• Historically, Operating Leases has averaged $399071.8 across 5 years, with a median of $377924.8 in 2021.
• Across the five-year window, Operating Leases sank 47.12% in 2022 and soared 164.48% in 2024, its largest moves.
• Year by year, Operating Leases stood at $519635.1 in 2021, then sank by 47.12% to $274790.2 in 2022, then dropped by 22.48% to $213015.3 in 2023, then surged by 164.48% to $563373.3 in 2024, then declined by 0.07% to $563000.0 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $563000.0 in Q4 2025, $404735.7 in Q3 2025, and $430862.4 in Q2 2025.